Latest Commercial Expansion News

EcoGraf Limited reveals a major breakthrough in its HFfree® graphite purification technology, cutting operating costs by 25% and projecting a US$282 million NPV for its initial 25,000 tonnes per annum facility. This positions the company as a competitive, eco-friendly supplier amid rising global demand and geopolitical shifts in battery materials.

Firebird Metals has received a significant Expression of Interest from Taza Metal Technologies to purchase up to five of its energy-efficient kilns, potentially generating over US$10 million in revenue. This marks a key step in Firebird’s international commercial expansion and highlights its leadership in sustainable manganese processing technology.

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.

Advanced Health Intelligence Ltd has secured up to AUD 5.5 million from Oakley Capital Partners to support its ASX reinstatement and global growth ambitions, while targeting an additional USD 6 million from strategic investors and unlocking AUD 3 million in R&D grants.

4DMedical has landed a $10 million strategic investment from Pro Medicus, aimed at accelerating its commercial growth and advancing its CT – VQ™ technology towards FDA clearance in the US.

4DMedical reports a 56% revenue surge in FY25 alongside a strategic $10 million investment from Pro Medicus, advancing its CT, VQ™ lung imaging technology towards FDA clearance.

Cardiex reported strong growth in its Pulse arterial health monitor sales during Q4 FY25, surpassing A$0.7 million for the year and advancing its transition to subscription-based digital health services.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

Decidr AI Industries reported an 82% revenue jump in its AI platform during Q4 FY25, launched AI Mentors with The Growth Faculty, and divested its 13Seeds business to sharpen focus on AI innovation.

xReality Group delivered a strong Q4 FY25 with $4.7 million in cash receipts, driven by growth in its Operator XR enterprise software and entertainment divisions, alongside a $2 million placement to institutional investors supporting international expansion.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.